MARKET

XLO

XLO

Xilio Therapeutics, Inc.
NASDAQ
0.7900
+0.0060
+0.77%
After Hours: 0.8099 +0.0199 +2.52% 19:46 03/21 EDT
OPEN
0.7840
PREV CLOSE
0.7840
HIGH
0.7900
LOW
0.7525
VOLUME
168.62K
TURNOVER
--
52 WEEK HIGH
1.930
52 WEEK LOW
0.5800
MARKET CAP
40.90M
P/E (TTM)
-0.7258
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at XLO last week (0310-0314)?
Weekly Report · 5d ago
Xilio Therapeutics reports Q4 results
Seeking Alpha · 03/11 13:36
XILIO THERAPEUTICS INC FILES FOR MIXED SHELF OF UP TO $250 MLN- SEC FILING
Reuters · 03/11 13:31
XILIO THERAPEUTICS : MAY OFFER, SELL SHARES OF COMMON STOCK OF UP TO $50 MLN FROM TIME TO TIME
Reuters · 03/11 12:52
Xilio Therapeutics, Inc. (XLO) Reports Q4 Loss, Lags Revenue Estimates
NASDAQ · 03/11 12:45
Xilio Therapeutics Q4 2024 GAAP EPS $(0.20) Beats $(0.21) Estimate, Xilio Anticipates That Its Cash And Cash Equivalents Of $55.3M As Of December 31, 2024, Together With The $52M Upfront Payments Received From AbbVie Is Expected To Provide Cash Runway Into Q1 Of 2026
Benzinga · 03/11 11:46
Xilio Therapeutics Provides Pipeline Progress Update and Anticipates Additional Vilastobart Data in Mid-2025
NASDAQ · 03/11 11:41
*Xilio Therapeutics 4Q Loss $13.1M >XLO
Dow Jones · 03/11 11:31
More
About XLO
Xilio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. It is using its proprietary platform to build a pipeline of novel, tumor-activated I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines, antibodies, bispecific and immune cell engagers. Its pipeline products include Vilastobart (XTX101), XTX301, XTX501, and tumor-activated bispecific molecules and immune cell-engaging molecules. XTX101 is an investigational tumor-activated, Fc-enhanced, high-affinity binding anti-CTLA-4 monoclonal antibody. XTX301, a tumor-activated, engineered interleukin 12, or IL-12, therapy.

Webull offers Xilio Therapeutics Inc stock information, including NASDAQ: XLO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XLO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading XLO stock methods without spending real money on the virtual paper trading platform.